NeoGenomics Laboratories
Cancer Reference laboratory.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $200m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 9 % | 5 % | 16 % | 12 % | 13 % | 11 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 9 % | (16 %) | (1 %) | 1 % | 7 % | 9 % | 12 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2 %) | (28 %) | (15 %) | (12 %) | (11 %) | (7 %) | (3 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5 % | 6 % | 5 % | 5 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
NeoGenomics, Inc., headquartered in Fort Myers, Florida, is a leading player in the cancer genetic testing and information services market. The company offers an extensive range of oncology-focused testing services designed to assist physicians in diagnosing and treating various types of cancer. These services include advanced methodologies such as cytogenetics, FISH (Fluorescence In Situ Hybridization), flow cytometry, IHC (Immunohistochemistry), ISH (In Situ Hybridization), and molecular testing.
NeoGenomics operates CAP-accredited and CLIA-certified laboratories across multiple locations, including Ft. Myers and Tampa, Florida, as well as Aliso Viejo, Carlsbad, and Fresno in California. These certifications ensure that the laboratories meet high standards for quality and reliability.
The company serves two primary client segments: healthcare providers and pharmaceutical companies. For healthcare providers, NeoGenomics offers a comprehensive menu of tests that help in the precise diagnosis and treatment of cancer. For pharmaceutical companies, the Pharma Services division supports clinical trials and drug development, contributing to the advancement of new cancer therapies. This division has shown significant growth, with a 39.3% increase in revenue, reaching $13.0 million in 2020.
NeoGenomics generates revenue through the provision of these specialized testing services. Healthcare providers pay for the diagnostic tests, while pharmaceutical companies fund the clinical trial and drug development services. The company also collaborates with other entities, such as QIAGEN, to develop companion diagnostic tests, further expanding its service offerings.
In summary, NeoGenomics stands out for its specialized focus on cancer diagnostics and its dual-service model catering to both healthcare providers and pharmaceutical companies. This positions the company well in the growing market for oncology diagnostics and personalized medicine.
Keywords: Cancer Genetic Testing, Oncology, Diagnostic Services, Clinical Trials, Drug Development, Cytogenetics, Flow Cytometry, Molecular Testing, Pharma Services, Companion Diagnostics.
Tech stack
Investments by NeoGenomics Laboratories
Edit
